IMed Group appoints new chief commercial officer

IMed Group has appointed Parminder Kalle as chief commercial officer as the organisation enters a new phase of international growth.

With more than 20 years’ experience across medical devices, diagnostics, pharma and digital health, Parminder combines technical expertise with a strong track record in commercial leadership. 

He will lead IMed’s global business development and growth strategy, strengthening the integration of its quality, regulatory and clinical services.

Parminder joins with a clear focus on building strategic partnerships and positioning IMed as a trusted global partner that supports clients through complex regulatory, reimbursement and market access environments. 

His approach blends technical rigour with commercial insight, ensuring services deliver both compliance and competitive advantage.

Parminder said: “IMed Group is entering an exciting phase of evolution. 

“Our strength lies in combining deep regulatory expertise with commercial strategy. 

“My focus is on driving growth through meaningful partnerships and helping our clients adapt quickly to industry change, turning compliance and quality into a platform for long-term success.”

Parminder’s appointment marks an important step in IMed Group’s plan to expand its international operations and enhance its end-to-end service offering across the Medtech sector.

Leeanne Baker, chief executive of IMed Group, added: “Parm brings a rare combination of technical expertise, commercial acumen and international experience. 

“His appointment strengthens our ability to deliver innovative, client-focused solutions across the global life sciences sector. 

“We are confident that his leadership will enable IMed Group to grow further while continuing to provide outstanding support to our clients.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.